Summary Topiramate was assessed in an open-label trial as broad-spectrum antiepileptic monotherapy, independently from the epilepsy type or syndrome. Adults and children aged 2 years and older, who were diagnosed with epilepsy within the last 5 years, treatment-naive or failing prior treatment with one antiepileptic drug (AED), received individually adjusted doses of topiramate, after escalation to 100 mg/day over 4 weeks (maximum 400 mg/day) or 3 mg/kg/day over 6 weeks (maximum 9 mg/ kg/day), respectively. Patients were followed for !7 months and optionally up to a maximum of 13 months. Data were analysed for all patients (n = 692), as well as for focal (n = 421) and generalized epilepsies (n = 148).
Introduction
Controlled double-blind trials for establishing efficacy in epilepsy commonly use fixed target doses in patients with a particular type of seizures. In clinical practice, however, patients eligible for monotherapy often do not yet have a clearly determined type of seizures or epilepsy syndrome at the time of drug initiation: accurate diagnosis develops over time. 1 Treatment is not only guided by the efficacy for the suspected epilepsy type, but also by the easiness of titration, the potential for pharmacokinetic interactions and the patient's individual response, with respect to both seizure control and tolerability. [2] [3] [4] Topiramate is a newer AED with a broad pharmacological profile, thereby providing the rationale for use as broad-spectrum anti-epileptic monotherapy. It is a sulfamate-substituted monosaccharide, with multiple mechanisms of action that include blockade of voltage-sensitive sodium channels, 5 potentiation of GABA A -evoked chloride flux, 6, 7 blockade of kainate/AMPA type of glutamate receptors, 8 and reduction of type L-calcium channels activity. 9 It also inhibits carbonic anhydrase. 10 As monotherapy, topiramate has been studied in patients with recent-onset epilepsy (within 3 months of study entry, maximum 2 years in one study), different age limits (either 3, 6 or 16 years), and various seizure types. [11] [12] [13] [14] These trials support a clinical efficacy of topiramate monotherapy in a broad range of dose strengths, usually established after titration to a fixed target dose (50, 100, 200, 400, 500 or 1000 mg/day). High doses of topiramate (1000 mg/day and 200-500 mg/day) were significantly more effective than low doses (100 mg/day and 25-50 mg/day, respectively) in reducing seizure frequency and time to exit due to seizures, but produced higher rates of side effects. 11, 12, 14 In most European countries, topiramate is indicated for adults and children as young as 2 years of age. It is authorised for adjuvant treatment of partial onset seizures with or without secondary generalisation, primary generalised tonic-clonic seizures and Lennox-Gastaut syndrome. More recently, it has also been approved as monotherapy for the same clinical conditions in a number of countries. The American Academy of Neurology and the American Epilepsy Society considered topiramate as one of the monotherapy options for newly diagnosed adolescents and adults with partial or mixed seizure disorders. 3, 4 Topiramate is the only AED that was retained for recommendation in the refractory types of partial and generalized epilepsy, and in Lennox Gastaut syndrome. 4 The objective of this study was to generate information on dose and outcome of topiramate monotherapy in a naturalistic setting: i.e. when topiramate is used as broad-spectrum AED at an individually adjusted dose, independently of initial seizure frequency and specific epilepsy type or syndrome. Although the limitations of such global treatment approach are recognized due to different prognoses by age and type of epilepsy, it reflects the reality of clinical practice in many countries where the degree of diagnostic ascertainment of specific epilepsy syndromes when treatment is initiated is low. An additional objective was thus to expand the current knowledge of response to topiramate in the most frequent epilepsy types or syndromes. Particular attention was given to the potential of topiramate in establishing full seizure freedom. Both children and adults were included.
Materials and methods

Patients
Seven hundred and fourteen patients (714) were recruited by 127 centres throughout Europe and the Middle East. Patients were eligible if they were at least 2 years of age, had a first diagnosis of epilepsy within the last 5 years and presented with any type of epileptic seizures. Epileptic seizures and epilepsy syndromes were classified according to the criteria of the International League Against Epilepsy (ILAE). 15, 16 Patients had to be treatment-naive or to be a non-responder to a first course of AED monotherapy, and not in need of combination treatment. Exclusion criteria were: pseudo-seizures or seizures with a treatable cause, such as metabolic disorders, toxic exposure, active infection or neoplasm; any 372 R. Guerrini et al.
237 patients completing the 1-year observation period. During the mandatory 7-month period of study, 8.8% of patients reported insufficient tolerability as a reason for dropout. The most frequent adverse event was paraesthesia. Our results support findings that emerge from controlled studies that topiramate is effective and well tolerated when used as initial or second monotherapy. They also suggest that in a naturalistic setting, overall good retention on treatment and seizure freedom are observed at low doses in a broad spectrum of epilepsies. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
clinically relevant progressive or serious illness expected to interfere with the patient completing the trial; pregnancy or lactation, history or suspicion of substance abuse, participation in an investigational drug trial in the 30 days prior to trial entry, previous use of topiramate or of more than one other AED, and hypersensitivity to tablet constituents.
Study design
This open trial included an initial titration period of 4 weeks in adults, 6 weeks in children, followed by a 6-month lasting monotherapy period, during which topiramate could be individually adjusted according to the response. Optionally, patients could continue the trial up to a maximum of 13 months or until the obligatory end of the study (set at 7 months after enrolment of the last patient in the study). Patients exited the study if they withdrew informed consent, prematurely stopped topiramate treatment, had insufficient seizure control at the maximum allowed dose (400 mg/day in adults, 9 mg/kg/day in children) or when another AED needed to be added to the treatment regimen. They also could be withdrawn if the investigator decided so for safety reasons.
The study was performed in accordance with the international rules of good clinical practice (Declaration of Helsinki). The protocol was approved by each centre's ethics committee or by an independent review board. Each patient or the patient's parent or legal guardian gave informed consent. The study was extensively monitored with detailed information completed at each visit and quality data management required for phase III studies.
Treatment
At trial entry, adults received 25 mg/day in the evening, followed by weekly increments of 25 mg/ day during 4 weeks until reaching the target dose of 100 mg/day, given b.i.d. as morning and evening gifts. Thereafter, the dose of topiramate could be adjusted in function of the patient's response with weekly increments or decrements of 25 mg/day, however, not exceeding 400 mg/day. In children, topiramate was started at 0.5 mg/kg/day in the evening, and escalated with 0.5 mg/kg/day during 6 weeks to the target dose of 3 mg/kg/day. Subsequent dose adjustment could not exceed 9 mg/kg/ day. If the patient used another AED at trial entry, this was gradually withdrawn, starting at week 2 of topiramate treatment, and over a period of three weeks or longer if indicated. Patients were treated for at least 7 months (6 months of monotherapy), and optionally for a maximum of 13 months or until trial end.
Evaluations
Patients were evaluated at start of the trial, at end of the titration (month 1), at the end of months 4 and 7, and if continuing beyond month 7, also at the end of months 10 and 13. At each visit, the investigator assessed the number and type of seizures. At start, these data were also reviewed retrospectively for the last month, as well as the last 6 months prior to trial entry. The 6-month retrospective information was used to calculate the baseline mean monthly seizure frequency. Global assessment was performed at start and at the 7-month and 13-month visits: the investigators rated the clinical global impression of the patient's medical condition on a 5-point scale (very good, good, reasonable, moderate or poor). The same 5-point scale was used to assess patients' and physicians' satisfaction at the 7-month and 13-month visits.
At each visit, physicians recorded adverse events, with their severity, relationship to topiramate treatment, and outcome. Each treatment-emergent physical and neurological abnormality was recorded as adverse event, as was any condition worsening or requiring initiation of medication. Weight was monitored throughout the trial.
Analysis and statistics
Safety data were analysed for the entire trial period in all subjects enrolled in the trial (any type of seizure; n = 692), efficacy data for those who had at least one post-baseline observation (intent-totreat analysis, regardless of compliance with the protocol, unless no trial medication had been taken at all). A 7-month and 13-month endpoint analysis was performed. Since only a limited number of patients (n = 237) among those that decided to continue the study beyond 7 months (n = 554) was able to complete the full 13-month trial period due to intervening trial closure (51% having to stop due to trial closure), the efficacy results at endpoint focus on the 7-month endpoint.
Mean monthly seizure frequencies during treatment were calculated based on the seizures cumulatively counted over the treatment period, from trial entry till each point of assessment. Mean and median values were calculated and the change versus baseline was assessed, using Wilcoxon signed-rank test, two-sided at the 5% significance level. Response rates were defined as the proportion of patients achieving !50, !75 and 100% reduction in mean monthly seizure frequency from trial entry versus the 6-month retrospective baseline. Response and seizure frequency assessments were performed for the total patient sample and the subgroups of patients with focal and generalised epilepsies or epilepsy syndromes. For the subgroup analysis, patients were classified by epilepsy syndrome, as assessed by the treating neurologist, while patients with absence seizures, situationrelated seizures or an undetermined or unknown classification were excluded.
Change in body weight during topiramate was assessed in adults !17 years, versus the value at start of the study and as a function of the initial body mass index (BMI; Wilcoxon signed rank test, twosided at the 5% significance level).
Results
Demography and disease characteristics
In total, 714 subjects were screened of whom 690 were included in the efficacy analysis, 692 in the safety analysis. The reasons for excluding patients from the efficacy or safety analysis were screening failures in 7 cases, and missing data on efficacy or on efficacy and safety in 2 and 15 patients, respectively. Baseline and disease characteristics are given in Table 1 . About half of the patients were male (50.9%), 17.5% were children aged 12 years or less and 9.5% were adolescents (13-16 years).
The mean time elapsed since the first diagnosis of epilepsy was 18.8 months, but its median was 3.0 months, indicating the majority of patients had a recent onset of epilepsy. The epilepsies or epilepsy syndromes were classified as focal in 62.9% of patients and generalized in 26.6%. In the month preceding trial entry, 86.1% of patients had suffered from seizures (for type, see Table 1 ). Overall, 64.6% of patients had a history of other disease (29.0% of the nervous system), 41.2% presented with one or more concomitant active diseases other than epilepsy, and 45.2% received various concomitant treatments.
Prior to trial entry, 42.9% of all patients enrolled had received monotherapy with one AED other than topiramate (see Table 1 for AED used). The reason for switching to topiramate was failure of efficacy in 61.6% of these patients, failure of tolerability in 24.9% and both in 13.1%. Failure of efficacy was the main reason to switch to topiramate for all prior AEDs, but tolerability was the single cause in more than one fourth of patients previously on carabamazepine or valproate, while it was involved as a reason for failure (with or without efficacy) in more than 40% of the patients on valproate, oxcarbazepine, lamotrigine and benzodiazepines.
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Completion/withdrawal information
The study retention during the mandatory 7-month study period, including 4-to 6-week titration and up to 6 months of monotherapy, was high (80%). The reasons for dropout are listed in Table 2 . The reasons were insufficient tolerability in 6.2% of patients, insufficient efficacy in 4.5% and both in 2.6%; 1.3% of patients withdrew consent. Among the 554 patients continuing beyond 7 months (optional follow-up period), a total of 3% dropped out because of insufficient efficacy and/or tolerability. Two hundred and thirty-seven patients completed the full 13-month treatment period (treatment was stopped earlier in 51% due to intervening trial closure).
Topiramate dosing
In the patients taking an AED prior to trial entry, the AED was tapered off within 25.6 (S.D. 15.6) days after starting topiramate. Fig. 1 illustrates the distribution of doses in adults at the 7-month endpoint. Table 3 lists the mean and median topiramate monotherapy doses, as well as their range, as used by adults (!17 years), adolescents (13-16 years), and children ( 12 years) at the 7-month endpoint. The median doses were 125 mg/day, 125 mg/day and 3.3 mg/kg/day, respectively: 100 mg was the most commonly used daily dose in adults, 42.9% used 100 mg daily.
Seizure response
Mean monthly seizure frequency at baseline was 11.2 (median 1.1, including all seizures) and was higher in focal than generalized epilepsies (Fig. 2 , excluding absences) and was significantly reduced at all visits during topiramate treatment, both in the total study population and the epilepsy subgroups ( p < 0.001 for change versus baseline).
Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting During the first 7 months of the study, 44.3% of patients were seizure-free (Fig. 3) . At the different visits, 72.0-83.0% of patients achieved at least 50% seizure reduction, and 65.0-69.7% at least 75% reduction. Table 4 lists the response rates at the 7-month endpoint, in the complete study population and each of the epilepsy subgroups. In the group with focal epilepsies, 39.4% of patients were seizure-free, while 73.9% achieved at least 50% seizure control. In the group with generalized epilepsies, 61.5% remained in remission, while 83.8% achieved at least 50% seizure reduction.
Similar response rates were obtained at the 13-month visit and at the 13-month endpoint: 35.3 and 40.8% of patients were seizure-free at these points, respectively. A Kaplan-Mayer analysis of the time-to-first seizure indicated that the majority of patients who relapsed (>40% of all the patients) did so within the first 6 weeks of the study, corresponding to the titration period.
Tolerability
Overall, adverse events were reported in 65.3% of patients, serious adverse events in 7.8%. Insufficient tolerability was a reason for dropout in a total of 8.8% of patients in the first 7 months and in 1.8% of patients followed between 7 and 13 months ( Table 2 ). The most frequent adverse events are listed in Table 5 . Paraesthesia was the most common adverse event (in 16% of patients), but rarely a reason to stop treatment (in less than 1%). Kidney stones were reported in two patients. This adverse event was not rated as 'serious', but it led to trial exit in one patient.
The causal relationship of adverse events was rated 'very likely' in 12.0% of the reported adverse events, 'probable' in 15.2% and 'possible' in 23.7%. In the majority of adverse events, no action was taken; in 7.6% of the events, the dose was adjusted and in 9.2%, topiramate was stopped permanently.
Body weight
Prior to trial entry, 55.2% of adult patients had a BMI below 25, while 44.8% were overweight to obese. During topiramate, mean weight (S.D.) decreased significantly from 73.4 kg (15.7) to 70.8 kg (15.6) at the 7-month endpoint. The effect was the most 376 R. Guerrini et al. Figure 3 Response rates during topiramate titration (month 1) and monotherapy (data at months 4-7, and at the 7-month endpoint): proportion of patients with at least 50%, 75% and 100% reduction in mean monthly seizure frequency from trial entry vs. baseline. [Data presented at a particular visit are based on the number of patients still in the trial and with data on seizures for that particular visit. The endpoint value includes the data from all patients at their last observation up to month 7.] Table 4 Response rates to topiramate monotherapy (intent-to-treat analysis): percentage of patients achieving at least 50, 75 and 100% reduction in mean monthly seizure frequency from trial entry versus baseline. pronounced during the first 4 months of topiramate treatment, after which it was maintained throughout the trial ( p < 0.001 for change versus baseline at all visits). Weight loss was more pronounced in overweight patients: at the 7-month endpoint, the mean weight change was À1.9 kg in patients with a BMI lower than 25 kg/m 2 , À2.6 kg in those with a BMI between 25 and 30 kg/m 2 , and À4.7 kg in patients with a BMI of at least 30 kg/m 2 ( p < 0.001 versus baseline in all BMI classes).
Clinical global impression and satisfaction
At the 7-month endpoint, the clinical global impression was rated by the investigators as 'very good' in 40.6% of patients, 'good' in 37.1% and 'reasonable' in 13.9%. The result was 'poor' in 3.8% of patients, and 'moderate' in 4.7%. Patient satisfaction with treatment was rated as 'very good' in 41.3% of the patients and 'good' in 30.8%. Similar rates of satisfaction were obtained by physician rating (40.7 and 30.3%, respectively).
Discussion
This study was performed in a mixed group of patients with a broad spectrum of epilepsies, either being treatment-naive or having failed one prior AED. Although such approach enrolling a broad spectrum of patients has restrictions, because epilepsies with different prognoses are pooled, it reflects clinical practice. Often, the exact diagnosis is not yet known when the patient presents first, and by the time AED treatment is started. Even in specialized centres, an epilepsy syndrome diagnosis or epilepsy classification is often difficult after the initial seizures. Diagnosis evolves with more certainty over time. Thus, in such circumstances, the use of a broad-spectrum AED is desirable, when treatment is needed.
This study shows that, in a setting closely following routine practice, a high-study retention can be obtained during flexibly dosed topiramate monotherapy (80%). Although the study is limited by its open design, the results suggest good tolerability and high adherence to treatment during topiramate monotherapy. Moreover, seizure control was achieved at topiramate dosages lower than those used in previous randomised controlled trials (median topiramate dose: 125 mg/day in adults and adolescents and 3.3 mg/kg/day in children below the age of 12). Over the total study period (titration inclusive), seizure freedom was observed in over 40% of patients. There were no major unexpected differences in efficacy between types of epilepsy.
Fairly sustained response rates were observed during 7-13 months in over 200 patients who were followed up for 1-year on monotherapy; the majority of relapses and dropouts had already occurred during the titration period. Long-term remission was thus obtained with topiramate in a majority of patients who completed the titration phase without seizures.
Comparison with other monotherapy studies of topiramate or other AEDs is hampered by differences in patient selection, trial design and, in particular, by the broad spectrum of epilepsies studied in this trial. Nevertheless, some aspects deserve discussion. The patient retention in this study was very high: only 20% of patients withdrew during the first 7 months. This observation is even more relevant when considering that 42.9% of patients enrolled in this study failed to respond to a prior AED for reasons of insufficient efficacy or tolerability. The dropout rate was similar to those reported for low-dosed topiramate in two controlled studies allowing dose adjustment (19-21%) . 12, 14 The 80% retention rate observed after 7 months in our study was higher than reported after 6-7 months monotherapy with other AEDs: below 68% with lamotrigine, [17] [18] [19] 43-56% with two different dosages of gabapentin, 20 56% with phenytoin, 18 56-65% with carbamazepine, 17, 20 and 57% with conventional AEDs, including carbamazepine, phenytoin and valproate. 19 However, one study in newly diagnosed epilepsy patients found comparable retention rates with topiramate 100 mg/day and carbamazepine 600 mg/day (fixed target doses), albeit lower than for valproate (1250 mg/day), 13 while another study comparing lamotrigine and carbamazepine (in adjustable doses) reported similar 6-month withdrawal rates as in our study. 21 The findings suggest that the ''flexible'' dose adjustment may be a factor contributing to longer retention of patients on treatment with AEDs. The high rate of patient retention we observed is also in line with the ratings of satisfaction with treatment, being 'good' to 'very good' in more than 70% of patients, both when rated by patients and physicians.
A second relevant observation is the high rate of seizure freedom, obtained in this study with lowdosed topiramate when used as first or second AED monotherapy for a broad spectrum of seizures. In an observational study of 525 patients, Kwan and Brodie reported seizure freedom in 69% of patients on follow-up, but only 47% had responded to the first AED, 13% to the second AED. 22 Many studies report rates of seizure freedom during 4-6 months of monotherapy with various AEDs, mostly varying between 32 and 60%. [17] [18] [19] 20, 23 Yet, comparison with these studies is difficult, not only because the patient populations may differ in types and severity of epilepsy, but also because the seizures, or the patients developing seizures, during the titration period were usually censored for calculation of the response during monotherapy: for instance, these accounted for 40-56% of patients on various doses of lamotrigine and carbamazepine in one study. 17 In our study, about 40% of patients had recurrences during the titration period, yet more than half of these patients continued in the trial. Despite the inclusion of the seizures during the titration period for calculation of the response rates, still more than 40% patients were seizurefree after 7-13 months of study. Overall, the response rates with topiramate in our study seem to compare well with those reported for other AEDs that currently are recommended for first-line use as monotherapy. In particular, our data suggest that topiramate may be effective at low monotherapy doses.
On the other hand, seizure freedom in our study was not as favourable as the rates that were reported after 6 months of topiramate monotherapy in newly diagnosed treatment-naive or prior treatment-responding patients (71% seizure-free with 50 mg/day, and 83% with 400 mg/day), 14 and in a small series of newly diagnosed adults (92% seizurefree with 200 mg/day). 24 In another study in patients with focal epilepsy, 12 the degree of seizure freedom observed at 4 months with 25-50 mg/day of topiramate was similar to the rate obtained in our study after 7 months (39%), while it was 54% with 200-500 mg/day of topiramate. However, the higher dose was associated with more adverse events. 12 Taken together, these observations indicate that patients with refractory focal epilepsy may benefit from further up-titration of topiramate until the optimal balance between seizure control and tolerability is reached. The rate of seizure freedom in the present study may also be not as high as expected from other studies, in part due to the rather heterogeneous patient sample. As can be noted from the mean baseline monthly seizure rates, a subset of our patients had fairly high seizure rate at start of treatment for newly diagnosed or new-onset epilepsies.
Overall, topiramate was well tolerated. Only 8.8% of patients withdrew in the first seven months because of lack of tolerability. Paraesthesia, the most common adverse event, was rarely a reason for withdrawal. Nephrolithiasis was observed in two (0.2%) patients, which compares to the incidence in the normal population. 25 Several ocular adverse events indicative of infection or aspecific ocular symptoms were reported, but there was no report of acute glaucoma. The effect of topiramate on weight was most pronounced in obese patients (BMI !30). This finding confirms earlier observations that topiramate may be advantageous in patients needing weight loss. 26, 27 In conclusion, in open naturalistic setting low, flexibly dosed topiramate appeared suitable for initiation, both as first and second-line monotherapy. In line with the controlled studies in specific epilepsy subtypes, it was found to result in good response rates, high patient retention and good tolerability, when used for a broad range of epilepsies.
